Hims and Hers Wegovy cost per month is easiest to answer as a ledger with three lines, because that is how the bill actually arrives. When Novo Nordisk opened branded Wegovy to telehealth platforms in April 2025, Hims and Hers advertised it starting at $599 per month for eligible cash-paying patients and the underlying pharmacy rate for the drug was about $499 per month. Through the manufacturer's own NovoCare Pharmacy channel, the self-pay rate has since been lowered from $499 to $349 per month, with a $199 per month introductory rate for the first two months of the two lowest doses. Our membership is one flat $299 per month for the doctor and the quarterly Biomarker Audit andthe medication is billed separately by the pharmacy at its own published price with zero markup from us. Those three numbers, $599, $349 and $299 plus the same drug at cost, are the whole comparison andthe rest of this article is the ledger behind them.
- Hims and Hers advertised branded Wegovy starting at $599 per month when it launched the drug in April 2025, with the underlying pharmacy rate about $499.
- Novo's own NovoCare Pharmacy channel lowered self-pay Wegovy from $499 to $349 per month, with a $199 two-month introductory rate through December 31, 2026.
- Lilly's self-pay Zepbound vials run $299 for the starting dose and up to $449 for higher doses through LillyDirect as of December 2025.
- Our membership is $299 per month flat for the doctor and four Biomarker Audits a year andthe pharmacy bills the medicine separately at cost with zero markup.
- A flat fee that never rises with the dose changes the titration conversation, because nobody in the model earns more when the dose climbs.
The full ledger, line by line
A weight loss bill has more lines than the headline number, so here is the arithmetic with each line named.
| Line item | Hims and Hers bundle, commonly reported | Manufacturer self-pay channel | GoodLife Health membership |
|---|---|---|---|
| Membership or program fee | About $599 per month bundled | No separate fee, drug priced directly | $299 per month flat |
| Wegovy medication | Included in the bundle, pharmacy rate about $499 | $349 per month standard, $199 intro for two months, through Dec 31 2026 | Billed by the pharmacy at its own price, $349 currently published for standard doses |
| Zepbound alternative | Sold on the same platform, prices vary | $299 starting dose, $449 higher doses via LillyDirect as of Dec 2025 | Billed by the pharmacy at its own price |
| Lab work before prescribing | Varies by program. Not always a full panel | Not included, no clinician relationship | Biomarker Audit included every 90 days, four a year |
| Doctor visits | Included, questionnaires plus messaging | Not included | Included, messaging plus video visits |
| Dose change penalty | None advertised, bundle price is flat | Drug price follows the dose | None on our side, fee never rises with the dose |
Read that table twice and one structural difference does the explaining. The bundled platforms fold the drug and the doctor into one number, which is convenient and also opaque. When one party prices both the medicine and the clinical judgment, the clinical judgment is no longer independent of the medicine. The manufacturer channel is transparent about the drug and sells nothing else, which is honest and also leaves you with a prescription and nobody reading your labs. The unbundled version is the third column andit exists precisely so those two decisions can be made independently.
Why the bundle price is higher than the manufacturer's own price
The $599 bundle versus the $349 self-pay drug is not a mystery and it is not a scandal. A telehealth bundle includes the platform, the clinical team, the shipping and the margin of the middleman andNovo Nordisk itself noted that each platform's price may be higher because it includes additional services. The consumer's job is simply to know what those additional services are worth. If the bundle includes real clinical care, quarterly labs and a clinician who reads them, part of the premium is buying something genuine. If the bundle includes a questionnaire and a shipping label, the premium is buying convenience and the clinical work is missing either way.
That question, what is inside the bundle, is where a careful buyer should spend the comparison time. Ask any platform these three things and write down the answers. What panel do you draw before the first prescription, by marker name. Who reads it andis that person the same one who adjusts the dose. And what happens at ninety days, a refill or a re-check. Platforms with strong answers to all three have earned part of their premium. Platforms that cannot answer the first question at all are selling the drug with a doctor attached as a formality.
What the flat fee version changes about the medicine itself
Our structure is deliberately different from both of the columns above. The membership fee is $299 per month and it covers the clinical relationship and four Biomarker Audits a year. It never covers medication andit never varies with medication. The prescription is written to your pharmacy and the pharmacy bills you at its own price, which is currently $349 per month for standard Wegovy doses through Novo's self-pay channel and $299 to $449 for Zepbound through LillyDirect depending on the dose. GoodLife Health sets nothing on that transaction, sees nothing and takes nothing. There is no molecule upcharge and no dose escalation fee, ever.
The consequence is not cosmetic. In a bundle, the platform's revenue is the bundle anda higher dose or a longer tenure is what the business is optimized for. In our model, the fee is identical whether you sit at the lowest effective dose or need the highest clinically required one, which means the titration decision can follow the medicine and the biomarkers instead of the revenue. The Stability-Seeking patient, the one who wants the least medicine that achieves the most result, is best served by a structure where nobody profits from escalation. That is the entire reason the model is unbundled.


What the clinical work before the prescription should look like
The price comparison is the smaller half of the decision. The larger half is whether the prescribing is grounded in measurement, because a GLP-1 written without a metabolic workup is a guess with a shipping label. The Biomarker Audit reads ApoB, Lp(a), hs-CRP, HbA1c, fasting insulin, a full lipid panel, a comprehensive metabolic panel, a CBC and TSH with reflex to free T4 andit is drawn every 90 days so the trend is visible rather than the snapshot. That panel answers the questions a weight loss questionnaire cannot. Is insulin resistance already driving the weight. Is the thyroid involved. Is cardiovascular risk being tracked while the weight comes off. Is there a contraindication that makes this medication the wrong first choice.
We prescribe branded, FDA-approved medication only. Wegovy and Ozempic are semaglutide and Zepbound and Mounjaro are tirzepatide andcash-pay patients who qualify for tirzepatide are routed to Zepbound while Mounjaro remains the insulin-covered diabetes channel. Compounded GLP-1 is never prescribed here, under any circumstance, because the dosing and purity claims of compounded copies are not something a clinician can stand behind. The FDA's own safety page on compounded semaglutide explains the risk in plain terms.
The titration math nobody advertises
Here is the calculation a careful reader should run before choosing any program andit is the calculation the bundlers do not print. Suppose a patient titrates down to the lowest effective dose in month eight because the panel shows the result is holding. On a bundle, the platform's monthly revenue is unchanged, so there is no economic event. On the manufacturer channel, the drug price follows the dose, so the patient saves. In our model both things are true at once. The fee stays $299 and the pharmacy line drops with the dose, so the total monthly cost falls and nobody's income is attached to preventing that.
Now run the same calculation in the other direction, because it matters for trust in both directions. If the panel shows the dose is not enough and a higher dose is clinically required, our fee does not rise. The pharmacy charges the higher dose price, which is the manufacturer's published number andwe take nothing from it. The patient pays for the medicine and nothing else changes. What this structure removes is the hidden third party, the program that earns more when the dose climbs and has no incentive to test whether a lower dose would hold the result.
The year one arithmetic, both models
Twelve months on our membership is $3,588, which covers four Biomarker Audits, the clinical relationship, messaging and video visits. Add the pharmacy line for whatever medication is indicated at the manufacturer's published self-pay price, currently $349 per month for standard Wegovy doses andthe year one total is roughly $7,776 for a patient on continuous Wegovy at that rate. The same year on a $599 bundle is $7,188 with the drug bundled in andthe difference in what you receive is the clinical layer, the quarterly panel and the independence of the prescribing decision.
We do not pretend that arithmetic makes us cheaper on the drug itself, because it does not. The manufacturer publishes its own price and we add nothing to it. What the arithmetic makes clear is what each dollar buys. The bundle buys convenience with a clinical layer of unknown depth. The manufacturer channel buys the drug with no clinical layer at all. The unbundled membership buys a known clinical layer at a known flat price, with the drug passed through at cost. Which of those three is worth the money is a judgment we would rather leave in your hands than obscure in a bundled number.
Who each option serves
The bundle serves the person who wants one number, one app and one shipment andwho is comfortable not knowing exactly how the clinical layer is built. The manufacturer self-pay channel serves the person who already has a trusted clinician who will order the labs and manage the prescription independently. The unbundled membership serves the person who wants the clinical layer specified in writing, the panel named by marker, the cadence fixed at ninety days and the prescribing decision free of any dose-linked revenue andwho wants all of that at $299 per month rather than at the top of the concierge price range.
If you arrive from another platform with an existing prescription, that is a normal path here. The first Biomarker Audit is scheduled within days of acceptance and the clinician reviews the current dose against the panel and your goals before anything changes. The eligibility check is free, takes a few minutes and never results in a charge unless a clinician accepts you into care.
Frequently Asked Questions
How much does Wegovy cost per month through Hims and Hers?
Hims and Hers advertised Wegovy starting at $599 per month for eligible cash-paying patients when it began offering the branded drug in April 2025, with the medication supplied at a pharmacy rate of about $499 per month. Telehealth bundles commonly run above the manufacturer self-pay rate because they fold services into the price. Confirm current pricing before you order, because these figures change.
What does Wegovy cost per month through the manufacturer's own channel?
Through NovoCare Pharmacy the self-pay rate was lowered from $499 to $349 per month, with a $199 per month introductory rate for the first two months of the two lowest doses. The offer runs through December 31, 2026 per Novo Nordisk's price guide.
What does the GoodLife Health membership cost compared with that?
The membership is one flat $299 per month covering the clinician relationship and four Biomarker Audits a year. The medication is billed separately by the pharmacy at its own price with zero markup, so a month totals $299 plus whatever Novo or Lilly publish for the drug.
Does the $299 fee include the medication?
No. The fee covers the doctor and the quarterly Biomarker Audit. The medicine is a separate charge billed directly by the pharmacy at pharmacy cost. One flat fee for the doctor, zero markup on the medicine.
Is the lowest effective dose cheaper at GoodLife Health?
The membership fee never rises with the dose, so a patient titrated down to the lowest effective dose pays the same $299. The pharmacy charges for the drug itself and the manufacturer prices the lower dose pen lower, so dose minimization also lowers the pharmacy line.
Does Hims and Hers check labs before prescribing Wegovy?
Policies evolve and we cannot speak for their current clinical protocol. At GoodLife Health a comprehensive Biomarker Audit before the first prescription is non-negotiable, because ApoB, HbA1c, fasting insulin, thyroid and inflammation markers decide whether the therapy is safe and what it should be paired with.
Can I keep my Hims or Ro prescription and switch to GoodLife Health?
Yes. You arrive with an existing prescription and history. The first Biomarker Audit is scheduled within days of acceptance and the clinician reviews the dose against the panel and your goals from there.
What happens if I stop paying the membership?
From month three the membership is month to month and you can cancel anytime. There is no contract and no cancellation fee and prescription decisions live with you and your clinician rather than with a subscription deadline.
One last thing
The honest summary of the comparison is that the bundle is a convenience product, the manufacturer channel is a drug product and the membership is a care product andthe prices are ordered accordingly once you unbundle them. If you want the drug alone at its best published price, buy it from the manufacturer and bring it to your own doctor. If you want the care layer specified in writing, with the panel named, the cadence fixed and the prescribing free of dose-linked revenue, that is what the $299 flat fee is for.
Related Guides
- Medical weight loss
- The GLP-1 pricing guide: Wegovy, Zepbound, Ozempic
- Is my GLP-1 dose too high? How the lowest effective dose is decided
- What a Biomarker Audit includes
References
- CNBC, Novo Nordisk opens Wegovy to telehealth, April 29, 2025. cnbc.com
- Novo Nordisk, Wegovy price guide, NovoCare Pharmacy, 2026. novocare.com
- Eli Lilly, Zepbound single-dose vial self-pay pricing, December 2025. investor.lilly.com
- FDA, medications containing semaglutide marketed for type 2 diabetes or weight loss. fda.gov